TISSIUM is a medtech company developing biomorphic programmable polymers for tissue reconstruction.

TISSIUM's mission is to disrupt the field of surgery and positively impact the lives of patients through the development of their platform of biomorphic programmable polymers.

TISSIUM was co-founded in 2013 by Robert Langer, Jeff Karp, Christophe Bancel, and Maria Pereira. The company is headquartered in Paris, France and Boston, USA.

TISSIUM is developing a portfolio of products that leverages its proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are the foundation of the company's technology platform. 

TISSIUM currently has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. TISSIUM's first nerve repair product COAPTIUM Connect is currently undergoing a first-in-human study in Australia.

TISSIUM's product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products.

TISSIUM is backed by BNP Paribas Développement, Sofinnova Partners, European Investment Fund (EIF), Bpifrance, Cathay Health, Fonds Stratégique des Transitions, Merieux Developpement, M&L Investments, Credit Mutuel Innovation, ValQuest Partners, and others. The company raised €50M ($53.6M) in a Series D round on May 23, 2023. This brings TISSIUM's total funding to around $200M to date.